Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors

Cancer Immunology, Immunotherapy

Volumn 57, Issue 6, 2008, Pages 883-895

  Yorty, Jodi L ^a,b   Tevethia, Satvir S ^a   Schell, Todd D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b ELIZABETHTOWN COLLEGE   (United States)

Author keywords

CD8+ T cells; Immunotherapy; SV40 T antigen; Transgenic mice

Indexed keywords

T LYMPHOCYTE ANTIGEN; VIRUS T ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN LEVEL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CHOROID PLEXUS TUMOR; CONTROLLED STUDY; FEMALE; KINETICS; LIFESPAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BRAIN; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES; FLOW CYTOMETRY; IMMUNE SYSTEM; IMMUNOTHERAPY; KINETICS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; NEOPLASMS; PEPTIDES;

EID: 43349085738     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0424-y     Document Type: Article

References (52)

1. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T (1989) Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293-303
2. Sibille C, Chomez P, Wildmann C, Van Pel A, De Plaen E, Maryanski JL de Bergeyck V, Boon T (1990) Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med 172:35-45
3. Gaugler B, Van den Eynde B, van der Burggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930
4. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436
5. Kast WM, Offringa R, Peters PJ, Voodrdouw AC, Meloen RH, van der Eb AJ, Melief CJ (1989) Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59:603-614
6. Klarnet JP, Kern DE, Okuno K, Holt C, Lilly F, Greenberg PD (1989) FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med 169:457-467
7. Tanaka Y, Tevethia MJ, Kalderon D, Smith AE, Tevethia SS (1988) Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virology 162:427-436
8. Kaech SM, Hemby S, Kersh E, Ahmed R (2002) Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:837-851
9. Hinrichs CS, Gattioni L, Restifo NP (2006) Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 18:363-370
10. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6:383-393
11. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, White DE, Rosenberg SA (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243-251
12. Dunn PL, North RJ (1991) Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor. J Leukoc Biol 49:388-396
13. Schell TD, Tevethia SS (2001) Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. J Immunol 167:6947-6956
14. Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE (2004) Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol 172:3462-3468
15. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516-7523
16. Gattinoni LS, Finkelstein E, Klebanoff CA, Antony PA, Palmer DC, Speiss PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202:907-912
17. Reits EA, Hodge JW, Herberts CA, Groothius TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259-1271
18. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357
19. Gattinoni L, Klebanoff CA, Palmer DC, Wrzensinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616-1626
20. Sussman JJ, Parihar R, Winstead K, Finkelman FD (2004) Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion. Cancer Res 64:9124-9130
21. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
22. Van Dyke T, Finlay C, Levine AJ (1985) A comparison of several lines of transgenic mice containing the SV40 early genes. Cold Spring Harb Symp Quant Biol 50:671-678
23. Schell TD, Mylin LM, Georgoff I, Teresky AK, Levine AJ, Tevethia SS (1999) Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J Virol 73:5981-5993
24. Mylin LM, Bonneau RH, Lippolis JD, Tevethia SS (1995) Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol 69:6665-6677
25. Ryan CM, Schell TD (2006) Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J Immunol 177:255-267
26. Palmiter RD, Chen HY, Messing A, Brinster RL (1985) SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice. Nature 316:457-460
27. Pretell J, Greenfield RS, Tevethia SS (1979) Biology of simian virus 40 (SV40) transplantation antigen (TrAg). V in vitro demonstration of SV40 TrAg in SV40 infected nonpermissive mouse cells by the lymphocyte mediated cytotoxicity assay. Virology 97:32-41
28. Mylin LM, Deckhut AM, Bonneau RH, Kierstead TD, Tevethia MJ, Simmons DT, Tevethia SS (1995) Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen. Virology 208:159-172
29. Deckhut AM, Lippolis JD, Tevethia SS (1992) Comparative analysis of core amino acid residues of H-2D(b)-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J Virol 66:440-447
30. Bonneau RH, Salvucci LA, Johnson DC, Tevethia SS (1993) Epitope specificity of H-2Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. Virology 195:62-70
31. Schell TD, Tevethia SS (2001) Cytotoxic T lymphocytes in SV40 infections. Methods Mol Biol 165:243-256
32. Mylin LM, Schell TD, Roberts D, Epler M, Boesteanu A, Collins EJ, Frelinger JA, Joyce S, Tevethia SS (2000) Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J Virol 74:6922-6934
33. Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS (2003) In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 171:697-707
34. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28:258-267
35. Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28:53-62
36. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ Jr, Rosenberg SA (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173:7125-7130
37. Wang LX, Li R, Yang G, Lim M, O'Hara A, Chu Y, Fox BA, Restifo NP, Urba WJ, Hu HM (2005) Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 65:10569-10577
38. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168-16173
39. Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S (1996) Isolation based on l-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res 56:4338-4342
40. North RJ (1984) Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother 16:175-181
41. Wang LX, Shu S, Plautz GE (2005) Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res 65:9547-9554
42. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP (2005) Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26:111-117
43. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591-2601
44. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H (2007) Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204:49-55
45. Blohm U, Potthoff D, van der Kogel AJ, Pircher H (2006) Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol 36:468-477
46. Hwang LN, Yu Z, Palmer DC, Restifo JP (2006) The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. Cancer Res 66:1132-1138
47. Van Dyke TA, Finaly C, Miller D, Marks J, Lozano G, Levine AF (1987) Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J Virol 61:2029-2032
48. Chakraborty M, Abrams Si, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW (2003) Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170:6338-6347
49. Schell TD (2004) In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. J Virol 78:1751-1762
50. Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH (2006) Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177:712-721
51. Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF (2004) T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 172:6057-6064
52. Schumacher TN (2002) T-cell-receptor gene therapy. Nat Rev Immunol 2:512-519